Supply of API for Primaxin generic brightens Orchid's prospects
This article was originally published in Scrip
Executive Summary
Orchid Chemicals & Pharmaceuticals expects business gains from its supply of the high-margin active pharmaceutical ingredient (API) for Hospira's generic version of Merck & Co's Primaxin (imipenem-cilastatin for intravenous injection) in the US.